- Home
- » Tags
- » Mogamulizumab
Top View
- New Drug Update
- IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
- (12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- Poteligeo, INN-Mogamulizumab
- Biosimilar Antibodies & ELISA Kits
- ONO PHARMACEUTICAL CO., LTD. Bristol-Myers Squibb Company Kyowa Hakko Kirin Co., Ltd
- Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Specialty Injectables Prior Authorization List
- Development of Therapeutic Antibodies for the Treatment Of
- CC Chemokines in a Tumor: a Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4
- Method for Measuring Anti-Drug Antibody
- C9050 Injection, Emapalumab-Lzsg, 1 Mg C9122
- Research-Grade Biosimilars
- Mogamulizumab-Kpkc) from MAVORIC Trial
- A New Tool for Management of Cutaneous T-Cell Lymphoma
- Mogamulizumab-Kpkc (Poteligeo®) by Kendall C
- Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies
- Recent Developments Regarding Periostin in Bronchial Asthma
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- A Phase 1 Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced Or Metastatic Solid Tumors
- Using Periostin As a Biomarker in the Treatment of Asthma Kenji Izuhara,1* Shoichiro Ohta,1 Junya Ono1,2
- Inflammation and Tumor Progression: Signaling Pathways and Targeted
- Prescribing Information for POTELIGEO
- Prior Authorization and Investigational Services List
- This Is the Headline
- Recent Developments Regarding Periostin in Bronchial Asthma
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Mogamulizumab-Kpkc for Mycosis Fungoides and Sézary Syndrome
- New Drug Update 2019
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Página 1 INEFECTIVIDAD DE MEDICAMENTOS BIOLÓGICOS
- Listes De DCI Proposées N'implique Aucune Recommandation En Vue De L'utilisation De La Substance Correspondante En Médecine Ou En Pharmacie
- Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3
- Prior Authorization — Premium
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Therapeutic Monoclonal Antibodies Approved by Food and Drug Administration in 2018 Henry Hongrong Cai MD, Nancy Kivel MD
- Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
- (INN) for Biological and Biotechnological Substances
- Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
- Biosimilar Monoclonalantibodies
- (Poteligeo) in the Treatment of Cancers: an Update Evidence from 14 Studies
- Poteligeo® (Mogamulizumab-Kpkc)
- (Rituximab) and Truxima (Rituximab-Abbs)- Updated Policy
- Minutes of PRAC Meeting on 26-29 October 2020
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem Cecilia Larocca, Thomas S
- (12) 按照专利合作条约所公布的国际申请w O 2016/050208
- POTELIGEO (Mogamulizumab-Kpkc) RATIONALE for INCLUSION IN
- Immunotherapy for Esophageal Squamous Cell Carcinoma
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Clinician-Administered Drugs Handbook
- Antibodies to Watch in 2018